Monograph Details
|
|
Respiratory Tract
> Lung surfactants/mucolytics
|
|
CUROSURF |
| Manufacturer |
|
DEY Pharma |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Lung surfactant. |
| Generic Name |
|
Poractant alfa (as phospholipids 80mg/mL and proteins 1mg/mL); susp for intratracheal administration; preservative-free. |
| Indications |
|
Treatment ("rescue") of respiratory distress syndrome (RDS) in premature infants. |
| Children |
|
See literature. Give by intratracheal administration through an endotracheal tube. Each dose should be administered as 2 aliquots. Inital dose of 2.5mL/kg birth weight; may give 2 more doses of 1.25mL/kg birth weight at 12-hour intervals. |
| Adults |
|
Not applicable. |
| Precautions |
|
Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully. |
| Adverse Reactions |
|
Bradycardia, hypotension, reflux of surfactant into endotracheal tube, others. |
| How Supplied |
|
Single-use vials (1.5mL, 3mL)—1 |
|
|
|
|
